Literature DB >> 10561346

Prognostic value of nucleolar protein p120 in patients with resected lung adenocarcinoma.

G Sato1, Y Saijo, B Uchiyama, N Kumano, S Sugawara, S Fujimura, M Sato, M Sagawa, K Ohkuda, K Koike, Y Minami, K Satoh, T Nukiwa.   

Abstract

PURPOSE: In this study we investigated the prognostic significance of proliferation-associated nucleolar protein p120 in primary resected lung adenocarcinoma because it reflects tumor growth fractions in vitro. PATIENTS AND METHODS: Expression levels of p120 in tumors were assessed by immunohistochemistry in 74 patients who underwent radical resection. With clinical follow-up data, the prognostic significance of p120 calculated by labeling indices was evaluated using the Cox proportional hazards model.
RESULTS: p120 protein was clearly detected in nucleoli of adenocarcinoma cells. Its expression levels widely varied in each sample from 8.5% to 67. 2%, with a mean +/- SD of 35.2% +/- 15.1%. No significant correlation was found between expression levels of p120 and clinicopathologic factors. However, the expression levels of p120 were negatively correlated with the tumor doubling time calculated with retrospective chest roentgenograms. Using a cutoff value of 35% in the labeling index of p120, patients with high expression of p120 experienced early recurrence and shorter survival compared with those who had low expression of p120. Multivariate analysis showed that p120 served as an independent, as well as the strongest, prognostic factor for resected lung adenocarcinoma.
CONCLUSION: This report provides the first evidence that expression levels of p120 in tumor tissues can be used as an independent and powerful prognostic marker for resected lung adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10561346     DOI: 10.1200/JCO.1999.17.9.2721

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  11 in total

1.  Ribosome biogenesis factor Tsr3 is the aminocarboxypropyl transferase responsible for 18S rRNA hypermodification in yeast and humans.

Authors:  Britta Meyer; Jan Philip Wurm; Sunny Sharma; Carina Immer; Denys Pogoryelov; Peter Kötter; Denis L J Lafontaine; Jens Wöhnert; Karl-Dieter Entian
Journal:  Nucleic Acids Res       Date:  2016-04-15       Impact factor: 16.971

2.  Prognostic Characteristics and Immune Effects of N6-Methyladenosine and 5-Methylcytosine-Related Regulatory Factors in Clear Cell Renal Cell Carcinoma.

Authors:  Lei Li; Zijia Tao; Yiqiao Zhao; Mingyang Li; Jianyi Zheng; Zeyu Li; Xiaonan Chen
Journal:  Front Genet       Date:  2022-04-27       Impact factor: 4.772

3.  Clinical significance of aberrant Wnt7a promoter methylation in human non-small cell lung cancer in Koreans.

Authors:  Tae-Hyung Kim; Ji-Yong Moon; Sang-Heon Kim; Seung Sam Paik; Ho Joo Yoon; Dong Ho Shin; Sung Soo Park; Jang Won Sohn
Journal:  J Korean Med Sci       Date:  2015-01-21       Impact factor: 2.153

Review 4.  The dynamic RNA modification 5-methylcytosine and its emerging role as an epitranscriptomic mark.

Authors:  Lukas Trixl; Alexandra Lusser
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-10-11       Impact factor: 9.957

Review 5.  Advances in RNA cytosine-5 methylation: detection, regulatory mechanisms, biological functions and links to cancer.

Authors:  Chen Xue; Yalei Zhao; Lanjuan Li
Journal:  Biomark Res       Date:  2020-09-14

Review 6.  The RNA Methyltransferase NSUN2 and Its Potential Roles in Cancer.

Authors:  Anitha Chellamuthu; Steven G Gray
Journal:  Cells       Date:  2020-07-22       Impact factor: 6.600

7.  Molecular Characterization Clinical and Immunotherapeutic Characteristics of m5C Regulator NOP2 Across 33 Cancer Types.

Authors:  Taisheng Liu; Jian Zhang; Chunxuan Lin; Guihong Liu; Guofeng Xie; Zili Dai; Peng Yu; Jian Wang; Liyi Guo
Journal:  Front Cell Dev Biol       Date:  2022-03-16

8.  M5C regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in lung adenocarcinoma.

Authors:  Hui Chen; Xiao-Lin Ge; Zhao-Yue Zhang; Ming Liu; Rui-Yan Wu; Xiao-Fei Zhang; Li-Ping Xu; Hong-Yan Cheng; Xin-Chen Sun; Hong-Cheng Zhu
Journal:  Transl Lung Cancer Res       Date:  2021-05

9.  Yeast Nop2 and Rcm1 methylate C2870 and C2278 of the 25S rRNA, respectively.

Authors:  Sunny Sharma; Jun Yang; Peter Watzinger; Peter Kötter; Karl-Dieter Entian
Journal:  Nucleic Acids Res       Date:  2013-08-02       Impact factor: 16.971

Review 10.  Disruption of the RNA modifications that target the ribosome translation machinery in human cancer.

Authors:  Maxime Janin; Laia Coll-SanMartin; Manel Esteller
Journal:  Mol Cancer       Date:  2020-04-02       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.